Tarsus Pharmaceuticals, Inc.·4

Mar 19, 7:04 PM ET

Mottiwala Aziz 4

4 · Tarsus Pharmaceuticals, Inc. · Filed Mar 19, 2026

Research Summary

AI-generated summary of this filing

Updated

Tarsus (TARS) CCO Mottiwala Aziz Sells 13,056 Shares

What Happened

Mottiwala Aziz, Chief Commercial Officer of Tarsus Pharmaceuticals (TARS), sold a total of 13,056 shares in three open-market transactions between March 17–19, 2026, generating approximately $892,528 in proceeds. The individual sales were: 4,286 shares at $69.42 for $297,534 (3/17), 4,330 shares at $68.71 for $297,514 (3/18), and 4,440 shares at $67.00 for $297,480 (3/19). These were sales (not purchases) and are reported as routine.

Key Details

  • Transaction dates and prices:
    • 2026-03-17: 4,286 shares @ $69.42 = $297,534
    • 2026-03-18: 4,330 shares @ $68.71 = $297,514
    • 2026-03-19: 4,440 shares @ $67.00 = $297,480
  • Total shares sold: 13,056; total proceeds: ≈ $892,528.
  • Shares owned after transaction: Not specified in the provided filing details.
  • Footnote: The sales were "sell-to-cover" transactions required by the issuer to satisfy tax withholding on vested Restricted Stock Units (RSUs); this was not a discretionary sell by the reporting person (Footnote F1).
  • Filing: Form 4 filed 2026-03-19 (covers transactions from 3/17–3/19); filing appears timely.

Context

These sales were mandated to cover tax withholding obligations tied to RSU vesting, which is a common administrative transaction and does not necessarily signal insider sentiment about the company. For retail investors, purchases are often more informative about insider confidence; required "sell-to-cover" transactions are routine.

Insider Transaction Report

Form 4
Period: 2026-03-17
Mottiwala Aziz
Chief Commercial Officer
Transactions
  • Sale

    Common Stock

    [F1]
    2026-03-17$69.42/sh4,286$297,53470,250 total
  • Sale

    Common Stock

    [F1]
    2026-03-18$68.71/sh4,330$297,51465,920 total
  • Sale

    Common Stock

    [F1]
    2026-03-19$67.00/sh4,440$297,48061,480 total
Footnotes (1)
  • [F1]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
Signature
/s/ Jeffrey Farrow, Attorney-in-Fact|2026-03-19

Documents

1 file
  • 4
    wk-form4_1773961455.xmlPrimary

    FORM 4